Examiner Cite

Kind

Country

Code2 i

.IP

.IP

.IP

Issue Date

Remove

Pages, Columns, Lines where

where Relevant

Figures Appear

Passages or Relevant

T5

X

X

×

Relevant Passages or Relevant

	1.44
	Filir
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Firs
	Art
(NOCTOT SUDMISSION UNGER 57 OF R 1.33)	Exa

Patent Number

Examiner Cite Foreign Document

1 45-7018B

2 06-185641A

3 2001-065714A

Application Number		10597990			
Filing Date		2006-08-15			
First Named Inventor Keen		e			
Art Unit		3753			
Examiner Name	Fox, .	John C.			
Attorney Docket Number		W-359-02 (WAT-005US)			

initiai-	NO		Code			of cited Docu	ment	Figure	es Appear
	1								
If you wis	h to add	d additional U.S. Pate	nt citatio	n inform	ation p	lease click the	Add button.		Add
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relev Figures Appear	
	1								
If you wis	h to add	d additional U.S. Publ	ished Ap			I n information p TENT DOCUM		d butto	n. Add Remove
in	Cit	Faccion Danisana	Causate		V:1	Dationia	Name of Patente		Pages,Columns,Lines

Kind Publication

1970-04-06

1994-07-08

2001-03-16

Corlet Date

U.S. PATENTS

Name of Patentee or Applicant

Applicant of cited

ASAHI ENG CO LTD

DAIKIN IND LTD

Document

JEOL LTD.

Initial* No Number3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10597990		
Filing Date		2006-08-15		
First Named Inventor Keen		2		
Art Unit		3753		
Examiner Name Fox,		John C.		
Attorney Docket Number		W-359-02 (WAT-005US)		

4	63-160475A	JP	1988-10-20	BABCOCK-HITACHI K K	×
5	07-071629A	JP	1995-03-17	COSMO TEX KK	×

If you wish to add additional Foreign Patent Document citation information please click the Add button

1 Add

		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher. (it	Тŝ
	1	Interrogation (Japanese and English translation) mailed January 17, 2012 assued by Japan Patent Office in related Japanese application No. 2007-501998 (13 pages)	×

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Date Considered

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at winer USPTO_GOV or MPEP 951.64. If better office that issued the document, by the two-letter code (WIPO Standard ST 3.). If the Uspace patent documents, the soliculation of the year of the regist of the register must preced the senial number of the patent document.

**Empirity of the Patent Standard ST and ST an

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10597990		
Filing Date		2006-08-15		
First Named Inventor	Keene			
Art Unit		3753		
Examiner Name	Fox, J	John C.		
Attorney Docket Number		W-359-02 (WAT-005US)		

CERTIFICATION STATEMENT

Please see	37	CFR 1	.97	and	1.98 t	o make	the	appropriate	selection(S	j
------------	----	-------	-----	-----	--------	--------	-----	-------------	------------	---	---

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 97 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Timothy P. Collins/	Date (YYYY-MM-DD)	2012-03-08
Name/Print	Timothy P Collins	Registration Number	58037

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.